BeOne Medicines Ag(NASDAQ) ONC

BeOne Medicines makes specialized treatments for people fighting cancer across the globe. The company develops medicine for blood cancers and solid tumors to help patients live longer lives. These therapies work by blocking specific proteins that allow cancer cells to grow and spread.

The Cancer Treatment Portfolio

• Hematology Medicines: Targeted therapies for blood cancers including BRUKINSA, which generated $3.9 billion in sales during 2025.
• Solid Tumor Therapies: Immune-based treatments like TEVIMBRA, a PD-1 inhibitor that helps the immune system find and kill cancer cells.
• In-Licensed Products: Portfolio of medicines from partners like Amgen and Recordati for bone cancer and rare diseases.
• Future Pipeline: Experimental compounds including BCL2 inhibitors and protein degraders currently in clinical testing for various malignancies.

Strategic Moves and Global Partnerships

• Redomiciled the corporate headquarters from the Cayman Islands to Switzerland in the second quarter of 2025.
• Partnered with Amgen to commercialize oncology products and co-fund global development through a $1.25 billion commitment.
• Acquired rights to develop and market POBEVCY in China through an agreement with Bio-Thera.
• Established an agreement with Luye Pharma to market BAITUOWEI, a treatment for prostate and breast cancer.
• Collaborated with Zymeworks and Jazz to develop and sell ZIIHERA in specific Asian and Oceania markets.

A Specialized Research Network

BeOne manages its own clinical trials with a team of 3,800 people instead of hiring outside research companies. This internal network allows the company to test new medicines faster and at a lower cost across six continents.

Performance by the Numbers

• Total global revenue reached $5.3 billion in 2025, an increase of 40.2% over the previous year.
• Net income hit $286.9 million in 2025, representing the company's first year of GAAP profitability.
• Free cash flow turned positive at $941.7 million during 2025, compared to a loss of $17.3 million in 2024.
• The company held $4.5 billion in cash and cash equivalents against $1 billion in debt as of December 31, 2025.

Evolution of the Business

BeOne has transitioned from a research-focused startup to a profitable, fully integrated global pharmaceutical firm. Its internal manufacturing and clinical development capabilities reduce reliance on third-party vendors for long-term growth.